NDAORALTABLET
Lifecycle
Pre-Launch
Data completeness
0/8 — Limited
Drug data last refreshed 15h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MILPREM-200 is an oral tablet combining conjugated estrogens with meprobamate, a combination hormone and anxiolytic agent. This fixed-dose combination targets menopausal symptoms and associated anxiety in women. The product represents a legacy combination approach addressing multiple symptom domains in menopause management.
Pre-Launch
Pre-launch status signals early-stage commercialization team building, with opportunities in market access, regulatory affairs, and initial brand strategy development.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on MILPREM-200 at Bausch Health offers early-stage launch experience in a competitive therapeutic area; however, zero linked job postings and pre-launch status indicate limited immediate hiring. Career growth depends on successful regulatory approval and commercial execution in a crowded menopause market.
Regulatory Affairs ManagerBrand Manager
Worked on MILPREM-200 at Bausch Health? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.